Oncocyte Corporation (OCX) ニュース

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land...

Oncocyte Announces August Investor Conferences Participation

IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics...

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology...

Form 8-K - Current report

MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode

HOLLAND, Mich., July 11, 2024 (GLOBE NEWSWIRE) -- MedTech Gurus, a leading podcast focused on the forefront...

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news...

Form 8-K - Current report

Oncocyte Appoints Andrea James as Chief Financial Officer

IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for...

Form 8-K - Current report

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to...

Form 8-K - Current report